Get the Stockscreener App
50.79
0.80%
-0.4408
Mirum Pharmaceuticals Inc stock is traded at $50.79, with a volume of 331.36K.
It is down -0.80% in the last 24 hours and up +20.83% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$51.23
Open:
$51.23
24h Volume:
331.36K
Relative Volume:
0.77
Market Cap:
$2.46B
Revenue:
$307.03M
Net Income/Loss:
$-99.81M
P/E Ratio:
-24.54
EPS:
-2.0695
Net Cash Flow:
$-27.20M
1W Performance:
+3.97%
1M Performance:
+20.83%
6M Performance:
+30.44%
1Y Performance:
+89.91%
1-Day Range:
$50.41
$52.53
1-Week Range:
$47.55
$53.49
52-Week Range:
$23.14
$53.49
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
50.79 | 2.46B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
(MIRM) Technical Pivots with Risk Controls - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Golden State Equity Partners Has $801,000 Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis - PR Web
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by SG Americas Securities LLC - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock - MarketBeat
Peter Radovich Sells 2,627 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Christopher Peetz Sells 9,102 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals president sells $126,680 in stock - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year HighTime to Buy? - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) shareholder returns have been solid, earning 192% in 5 years - Simply Wall St
Major Insider Stock Sales at Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals president sells $126,680 in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mirum Pharmaceuticals stock soars to all-time high of $49.59 - MSN
Mirum Pharmaceuticals stock soars to all-time high of $49.59 By Investing.com - Investing.com UK
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why - Yahoo Finance
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Mirum Pharmaceuticals SVP sells shares worth $43,227 By Investing.com - Investing.com Australia
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of Stock - MarketBeat
Christopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals CEO sells shares worth $327,658 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals SVP sells shares worth $43,227 - Investing.com India
Mirum Pharmaceuticals CEO sells shares worth $327,658 - Investing.com India
Mirum Pharmaceuticals president sells $152,256 in stock By Investing.com - Investing.com Canada
(MIRM) Long Term Investment Analysis - Stock Traders Daily
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
FY2024 EPS Estimates for MIRM Increased by Leerink Partnrs - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for MIRM Earnings - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month HighShould You Buy? - MarketBeat
As Biotech Trade Gets Wonky, I'm Eyeing Two Clinical-Stage Companies - RealMoney
Cantor Fitzgerald Comments on MIRM FY2025 Earnings - Defense World
Mirum Pharmaceuticals stock soars to all-time high of $48.94 By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for MIRM FY2025 Earnings - MarketBeat
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock By Investing.com - Investing.com Australia
Joanne Quan Sells 6,969 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Biliary Atresia Market to Expand Significantly by 2034, States DelveInsight Report | Albireo Pharma, Mirum Pharmaceuticals - Barchart
Mirum Pharmaceuticals' chief medical officer sells $319,598 in stock - MSN
Financial Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) & Eyenovia (NASDAQ:EYEN) - Defense World
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results - MSN
(MIRM) Investment Report - Stock Traders Daily
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Feb 03 '25 |
Sale |
48.22 |
9,102 |
438,921 |
115,920 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Feb 03 '25 |
Sale |
48.22 |
1,064 |
51,309 |
4,232 |
| Radovich Peter | PRESIDENT AND COO |
Jan 24 '25 |
Sale |
47.92 |
3,177 |
152,256 |
29,588 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jan 24 '25 |
Sale |
47.92 |
902 |
43,228 |
3,524 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jan 24 '25 |
Sale |
47.92 |
6,837 |
327,658 |
125,022 |
| Quan Joanne | CHIEF MEDICAL OFFICER |
Jan 17 '25 |
Sale |
45.86 |
6,969 |
319,598 |
5,649 |
| Radovich Peter | PRESIDENT AND COO |
Jan 07 '25 |
Sale |
42.82 |
1,998 |
85,545 |
27,015 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jan 07 '25 |
Sale |
42.82 |
7,489 |
320,644 |
119,359 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jan 07 '25 |
Sale |
42.82 |
750 |
32,111 |
2,926 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Nov 14 '24 |
Option Exercise |
2.94 |
2,500 |
7,350 |
4,926 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):